New combo aims to tame chemo side effects in tough lung cancer

NCT ID NCT05578326

First seen Apr 04, 2026 · Last updated Apr 30, 2026 · Updated 4 times

Summary

This study tests whether adding trilaciclib to the standard drug lurbinectedin can lower the risk of dangerous low white blood cell counts (neutropenia) in people with advanced small cell lung cancer that has stopped responding to initial treatment. About 30 adults will receive the combination, and researchers will track how many develop severe neutropenia and how long it lasts. The goal is to make treatment safer without reducing its cancer-fighting power.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dartmouth Hitchcock Medical Center

    WITHDRAWN

    Lebanon, New Hampshire, 03756, United States

  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.